ART010

A novel biologic to treat bone cancer, ART010 is a modified version of osteoprotegerin, a naturally occurring protein in the body that regulates bone density.

Osteoprotegerin has been shown to protect against loss of bone mass in diseases such as osteoporosis and bone cancer. However, there is evidence that osteoprotegerin may interfere with a surveillance system in the body that kills cancer cells.

ART010 is an engineered version of osteoprotegerin, produced by the application of Arana’s technology platform EvoGene™, that protects against bone loss without interfering with the cancer surveillance system.

In preclinical studies, ART010 was shown not only to protect against bone loss as effectively as the osteoprotegerin, but also to reduce the ability of a tumour to grow in bone.

Seventy percent of patients with advanced breast and prostate cancer develop secondary cancers in the bone, which amounts to about 300,000 new cases annually in the US alone. The cost of adjunct treatment to counter the effects of bone erosion, fragility and pain is estimated at US$1 billion.